PT3336192T - Vetor de transcrição de rna e utilizações do mesmo - Google Patents

Vetor de transcrição de rna e utilizações do mesmo

Info

Publication number
PT3336192T
PT3336192T PT181531336T PT18153133T PT3336192T PT 3336192 T PT3336192 T PT 3336192T PT 181531336 T PT181531336 T PT 181531336T PT 18153133 T PT18153133 T PT 18153133T PT 3336192 T PT3336192 T PT 3336192T
Authority
PT
Portugal
Prior art keywords
rna transcription
transcription vector
vector
rna
transcription
Prior art date
Application number
PT181531336T
Other languages
English (en)
Original Assignee
Univ Brussel Vrije
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Brussel Vrije filed Critical Univ Brussel Vrije
Publication of PT3336192T publication Critical patent/PT3336192T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/7105Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596Molecules with a "CD"-designation not provided for elsewhere
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55516Proteins; Peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/50Methods for regulating/modulating their activity
    • C12N2320/52Methods for regulating/modulating their activity modulating the physical stability, e.g. GC-content
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00Vectors comprising a targeting moiety
    • C12N2810/10Vectors comprising a non-peptidic targeting moiety
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/50Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00Vectors comprising a special translation-regulating system
    • C12N2840/10Vectors comprising a special translation-regulating system regulates levels of translation
    • C12N2840/105Vectors comprising a special translation-regulating system regulates levels of translation enhancing translation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
PT181531336T 2013-11-12 2014-11-12 Vetor de transcrição de rna e utilizações do mesmo PT3336192T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13192555 2013-11-12

Publications (1)

Publication Number Publication Date
PT3336192T true PT3336192T (pt) 2022-03-10

Family

ID=49578161

Family Applications (2)

Application Number Title Priority Date Filing Date
PT181531336T PT3336192T (pt) 2013-11-12 2014-11-12 Vetor de transcrição de rna e utilizações do mesmo
PT147999965T PT3068888T (pt) 2013-11-12 2014-11-12 Vetor de transcrição de rna e utilizações do mesmo

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT147999965T PT3068888T (pt) 2013-11-12 2014-11-12 Vetor de transcrição de rna e utilizações do mesmo

Country Status (19)

Country Link
US (3) US10159755B2 (pt)
EP (2) EP3068888B1 (pt)
JP (2) JP6530393B2 (pt)
KR (2) KR102396589B1 (pt)
CN (2) CN111621524A (pt)
AU (1) AU2014350222B2 (pt)
CA (2) CA2929203C (pt)
DK (2) DK3068888T3 (pt)
EA (1) EA035313B1 (pt)
ES (2) ES2908268T3 (pt)
HU (2) HUE038831T2 (pt)
IL (1) IL245596B (pt)
MX (1) MX2016006134A (pt)
NO (1) NO3068888T3 (pt)
NZ (1) NZ720885A (pt)
PL (2) PL3068888T3 (pt)
PT (2) PT3336192T (pt)
SG (1) SG11201603482RA (pt)
WO (1) WO2015071295A1 (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9458450B2 (en) 2012-03-15 2016-10-04 Flodesign Sonics, Inc. Acoustophoretic separation technology using multi-dimensional standing waves
US9950282B2 (en) 2012-03-15 2018-04-24 Flodesign Sonics, Inc. Electronic configuration and control for acoustic standing wave generation
US10967298B2 (en) 2012-03-15 2021-04-06 Flodesign Sonics, Inc. Driver and control for variable impedence load
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
WO2015105955A1 (en) 2014-01-08 2015-07-16 Flodesign Sonics, Inc. Acoustophoresis device with dual acoustophoretic chamber
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11021699B2 (en) 2015-04-29 2021-06-01 FioDesign Sonics, Inc. Separation using angled acoustic waves
US11474085B2 (en) 2015-07-28 2022-10-18 Flodesign Sonics, Inc. Expanded bed affinity selection
US11459540B2 (en) 2015-07-28 2022-10-04 Flodesign Sonics, Inc. Expanded bed affinity selection
WO2017025447A1 (en) * 2015-08-10 2017-02-16 Curevac Ag Method of increasing the replication of a circular dna molecule
US11085035B2 (en) 2016-05-03 2021-08-10 Flodesign Sonics, Inc. Therapeutic cell washing, concentration, and separation utilizing acoustophoresis
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
CA3041517A1 (en) 2016-10-19 2018-04-26 Flodesign Sonics, Inc. Affinity cell extraction by acoustics
WO2019118921A1 (en) 2017-12-14 2019-06-20 Flodesign Sonics, Inc. Acoustic transducer drive and controller
AU2020204781A1 (en) 2019-01-04 2021-08-12 Etherna Immunotherapies Nv mRNA vaccine
JP7650507B2 (ja) * 2019-03-13 2025-03-25 イーザアールエヌーエー イムノセラピーズ エンヴェー mRNAワクチン
US20220362360A1 (en) * 2019-04-26 2022-11-17 Etherna Immunotherapies Nv Mrna formulation
JP2022540759A (ja) 2019-06-27 2022-09-20 イーザアールエヌーエー イムノセラピーズ エンヴェー 併用療法
KR20230002300A (ko) 2020-01-21 2023-01-05 이더알엔에이 이뮤노테라피스 엔브이 지질 나노입자
KR20230004447A (ko) * 2020-02-14 2023-01-06 이더알엔에이 이뮤노테라피스 엔브이 비강 내 mRNA 백신
BR112022025217A2 (pt) 2020-06-11 2023-01-03 Etherna Immunotherapies Nv Nanopartículas lipídicas
JP7808695B2 (ja) * 2022-01-27 2026-01-29 エスケー バイオサイエンス カンパニー リミテッド タンパク質発現のためのmRNA及びそのための鋳型
KR102669481B1 (ko) 2022-03-15 2024-05-28 주식회사 협일공조 필터교체가 용이한 디퓨저
KR102624969B1 (ko) * 2023-04-03 2024-01-16 한국과학기술원 mRNA 번역 증가를 유도하는 mRNA 3'UTR 서열
WO2025014191A1 (ko) * 2023-07-07 2025-01-16 에스케이바이오사이언스(주) 단백질 발현을 위한 rna 및 이를 위한 주형
WO2025087253A1 (zh) * 2023-10-23 2025-05-01 康希诺(上海)生物研发有限公司 一种用于体外转录mRNA的质粒载体、构建方法及其应用
TW202535429A (zh) 2023-12-22 2025-09-16 比利時商eTheRNA免疫治療公司 包含5'utr-3'utr組合的多核苷酸及其用途
TW202541786A (zh) 2023-12-22 2025-11-01 比利時商eTheRNA免疫治療公司 脂質奈米顆粒
WO2025195370A1 (zh) * 2024-03-18 2025-09-25 康希诺(上海)生物研发有限公司 一种mRNA体外表达质粒、构建方法及其应用
WO2026044087A1 (en) 2024-08-21 2026-02-26 Shape Therapeutics Inc. Increased cellular stability for aav production
WO2026073032A1 (en) 2024-09-27 2026-04-02 Shape Therapeutics Inc. Constructs for improved aav production

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IS2334B (is) 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
US6043358A (en) 1995-11-01 2000-03-28 Merck & Co., Inc. Hexahydro-5-imino-1,4-heteroazepine derivatives as inhibitors of nitric oxide synthases
US5861240A (en) * 1996-02-28 1999-01-19 The Regents Of The University Of California Isolated human herpesvirus type 8 sequences and uses thereof
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US7183395B2 (en) * 2000-01-28 2007-02-27 The Scripps Research Institute Methods of identifying synthetic transcriptional and translational regulatory elements, and compositions relating to same
US7468275B2 (en) * 2000-01-28 2008-12-23 The Scripps Research Institute Synthetic internal ribosome entry sites and methods of identifying same
US7608699B2 (en) * 2003-12-29 2009-10-27 Rockefeller University Synthetic nuclear localization signal derived from lentiviral integrase and methods of use thereof
WO2005117989A1 (en) * 2004-06-04 2005-12-15 Centre National De La Recherche Scientifique Drugs for the prevention or treatment of immunodeficiencies, autoimmune diseases or for the induction of immune tolerance
JP4964493B2 (ja) * 2006-04-28 2012-06-27 株式会社カネカ 内部リボソーム結合部位を利用した遺伝子組換え全抗体の効率的生産法
US8476419B2 (en) 2007-09-14 2013-07-02 Vrije Universiteit Brussel Enhancing the T-cells stimulatory capacity of human antigen presenting cells and their use in vaccination
WO2009075886A1 (en) 2007-12-11 2009-06-18 The Scripps Research Institute Compositions and methods related to mrna translational enhancer elements
US20120124701A1 (en) * 2008-02-01 2012-05-17 Ceres, Inc. Promoter, promoter control elements, and combinations, and use thereof

Also Published As

Publication number Publication date
KR20160090317A (ko) 2016-07-29
NO3068888T3 (pt) 2018-06-30
EP3336192B1 (en) 2021-12-08
PL3068888T3 (pl) 2018-07-31
US20180353625A1 (en) 2018-12-13
EP3336192A1 (en) 2018-06-20
US10159755B2 (en) 2018-12-25
ES2666380T3 (es) 2018-05-04
CN111621524A (zh) 2020-09-04
CA3191243A1 (en) 2015-05-21
JP6900054B2 (ja) 2021-07-07
US20210060182A1 (en) 2021-03-04
WO2015071295A1 (en) 2015-05-21
JP6530393B2 (ja) 2019-06-12
EP3068888B1 (en) 2018-01-31
US20160279266A1 (en) 2016-09-29
KR20210076181A (ko) 2021-06-23
JP2019146589A (ja) 2019-09-05
BR112016010595A2 (pt) 2017-12-05
EP3068888A1 (en) 2016-09-21
KR102396589B1 (ko) 2022-05-10
SG11201603482RA (en) 2016-05-30
ES2908268T3 (es) 2022-04-28
EA201690965A1 (ru) 2016-09-30
CN105849269A (zh) 2016-08-10
CA2929203C (en) 2023-04-18
US10864284B2 (en) 2020-12-15
KR102267412B1 (ko) 2021-06-21
DK3068888T3 (en) 2018-05-07
HUE038831T2 (hu) 2018-11-28
IL245596A0 (en) 2016-06-30
AU2014350222A1 (en) 2016-06-23
JP2016537978A (ja) 2016-12-08
HK1226097A1 (zh) 2017-09-22
HUE058792T2 (hu) 2022-09-28
CN105849269B (zh) 2020-07-17
AU2014350222B2 (en) 2020-02-27
DK3336192T3 (da) 2022-03-14
IL245596B (en) 2019-10-31
CA2929203A1 (en) 2015-05-21
PL3336192T3 (pl) 2022-04-04
MX2016006134A (es) 2017-01-20
NZ720885A (en) 2022-02-25
PT3068888T (pt) 2018-04-24
EA035313B1 (ru) 2020-05-27

Similar Documents

Publication Publication Date Title
IL245596A0 (en) A vector for rna transcription and its uses
IL276106A (en) Garp-binding proteins and their uses
IL269461B (en) Cytidine-5-carboxamide modified nucleotide preparations and related methods
GB2535911B (en) Strigolactone formulations and uses thereof
GB201317889D0 (en) Product and use
EP2988742A4 (en) THIAZOLES AND USES THEREOF
IL245839A0 (en) Inhibitors of rna polymerase i and use of preparations containing them for treatment
EP3048538A4 (en) Vector operation core and vector processor
PL2964767T3 (pl) Geny kodujące toksyny i sposoby ich zastosowania
AP2016009207A0 (en) Genetic markers and uses therefor
SG11201600235TA (en) Castings and manufacture methods
GB201310350D0 (en) Curable compositions and membranes
EP2964610A4 (en) VINYL SULFON-BASED 18F LABELING COMPOSITIONS AND METHOD AND USES THEREOF
GB201309178D0 (en) Enzyme and uses thereof
ZA201601880B (en) Hetero-transglycosylase and uses thereof
GB201320992D0 (en) Complex and uses thereof
WO2014202624A9 (en) Rasamsonia gene and use thereof
GB201305297D0 (en) Novel agents and uses thereof
GB201304585D0 (en) Methods and product
GB201301393D0 (en) Kiddibidet and pottibidet
GB201304166D0 (en) CelebQuiff and Instant Quiff
GB201318949D0 (en) Genes
GB201309328D0 (en) Product and use thereof
GB201306435D0 (en) Vector
GB201301640D0 (en) Methods and peptides